Company News
11/02/2023
RIVANNA Receives $2.9M NIH Grant to Expand Accuro 3S Applications
RIVANNA®, developers of world-first, imaging-based medical solutions, announced they received a $2.9 million grant from the National Institutes of Health (NIH). The grant will further the development of Accuro® 3S, designed for image-guided regional anesthesia, to broaden access to opioid-sparing analgesia for hip fracture pain. Each year, over 330,000 Americans face hospitalization due to hip …
11/01/2023
TearSolutions, Inc. Appoints Robert Dempsey to its Board of Directors
TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED) and other ocular surface related diseases, today announced that Robert Dempsey has been appointed to the Company’s Board of Directors. “Robert is a proven industry leader with extensive and highly relevant experience in Ophthalmology and DED,” …
10/31/2023
BRAINBox Solutions Announces Initial Series B Investments to Support U.S. Regulatory Clearance, Initial Commercialization of BRAINBox TBI Concussion Diagnostic/Prognostic Test
BRAINBox Solutions today announced initial investments into the company’s Series B financing to support U.S. regulatory clearance and initial commercialization of its BRAINBox TBI concussion diagnostic/prognostic test in adults and completion of a clinical study in pediatric patients. Genoa Ventures is leading the financing, which includes other current and new investors. “We have made significant …
10/30/2023
ATCC and USP Launch First Set of Products to Advance Quality and Reduce Risk in the Development of Biological Therapeutics and Vaccines
ATCC and U.S. Pharmacopeia (USP), two premier materials management and standards organizations, announced the launch of their first set of joint products to advance the quality control and reduce the risk in the manufacturing of biological therapies and vaccines. This initial set of six products consists of highly characterized and pure genomic DNA (gDNA) from cell …
10/30/2023
FDA approves muscular dystrophy drug built on Children’s National research
Boys with Duchenne muscular dystrophy (DMD) have a clinically proven, new treatment option with the Food and Drug Administration’s approval Thursday of vamorolone, a steroidal-type, anti-inflammatory drug developed based on research performed at Children’s National Hospital. Created by ReveraGen BioPharma Inc., vamorolone has a molecular structure similar to traditional corticosteroids, which are currently used to …
10/26/2023
Ceres Nanosciences Establishes Five New Wastewater-Based Epidemiology Centers of Excellence Under NIH RADx Initiative
Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of five new wastewater-based epidemiology centers of excellence at the Houston Health Department, Morgan State University, the Nebraska Public Health Laboratory, the State Hygienic Laboratory at the University of Iowa, and the …